Citius Oncology, Inc. (NASDAQ:CTOR) Short Interest Update

Citius Oncology, Inc. (NASDAQ:CTOR) was the target of a large decline in short interest in February. As of February 13th, there was short interest totaling 913,552 shares, a decline of 24.7% from the January 29th total of 1,213,142 shares. Based on an average trading volume of 183,334 shares, the short-interest ratio is currently 5.0 days. Approximately 1.1% of the company’s stock are sold short. Approximately 1.1% of the company’s stock are sold short. Based on an average trading volume of 183,334 shares, the short-interest ratio is currently 5.0 days.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Citius Oncology in a research note on Monday, December 22nd. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Citius Oncology currently has an average rating of “Hold” and an average price target of $6.00.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of CTOR. Arkadios Wealth Advisors acquired a new position in Citius Oncology during the 2nd quarter valued at $51,000. Geode Capital Management LLC lifted its stake in shares of Citius Oncology by 179.0% in the second quarter. Geode Capital Management LLC now owns 57,297 shares of the company’s stock valued at $249,000 after buying an additional 36,758 shares during the period. Jane Street Group LLC acquired a new stake in Citius Oncology during the second quarter worth about $465,000. Bank of America Corp DE increased its stake in Citius Oncology by 5,256.9% during the second quarter. Bank of America Corp DE now owns 8,571 shares of the company’s stock valued at $37,000 after acquiring an additional 8,411 shares during the period. Finally, Citadel Advisors LLC acquired a new position in Citius Oncology in the 3rd quarter valued at approximately $36,000. 70.52% of the stock is currently owned by institutional investors and hedge funds.

Citius Oncology Stock Performance

Shares of NASDAQ:CTOR traded down $0.04 during trading on Monday, reaching $1.08. The stock had a trading volume of 97,598 shares, compared to its average volume of 196,670. The company has a quick ratio of 0.32, a current ratio of 0.83 and a debt-to-equity ratio of 0.07. The stock has a fifty day simple moving average of $1.12 and a two-hundred day simple moving average of $1.44. The firm has a market capitalization of $95.34 million, a price-to-earnings ratio of -3.48 and a beta of 3.02. Citius Oncology has a 52 week low of $0.55 and a 52 week high of $6.19.

Citius Oncology (NASDAQ:CTOR) last posted its earnings results on Friday, February 13th. The company reported ($0.06) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.06). The firm had revenue of $3.94 million during the quarter, compared to analyst estimates of $4.37 million.

Citius Oncology Company Profile

Citius Oncology, Inc is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. The company was founded on March 1, 2021 and is headquartered in Cranford, NJ.